Trials / Terminated
TerminatedNCT02415595
Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults
A Phase 2b Randomized, Active-Controlled, Double-Blind Trial to Investigate Safety, Efficacy, and Dose-response of BMS-955176, Given on a Backbone of Tenofovir/Emtricitabine, in Treatment-Naive HIV-1 Infected Adults
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 210 (actual)
- Sponsor
- ViiV Healthcare · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find at least one dose of BMS-955176 that will be safe, effective and tolerable for HIV-1 infected treatment naive adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-955176 | HIV Maturation Inhibitor |
| DRUG | EFV | EFV |
| DRUG | TDF/FTC | TDF/FTC |
Timeline
- Start date
- 2015-05-12
- Primary completion
- 2016-05-26
- Completion
- 2017-08-21
- First posted
- 2015-04-14
- Last updated
- 2018-09-19
- Results posted
- 2018-09-19
Locations
64 sites across 12 countries: United States, Argentina, Canada, Chile, France, Germany, Italy, Mexico, Poland, South Africa, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT02415595. Inclusion in this directory is not an endorsement.